Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays

European Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2004, Pages 265-268

  Daley Yates, P T ^a   Kunka, R L ^b   Yin, Y ^b   Andrews, S M ^b   Callejas, S ^a   Ng, C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Fluticasone propionate; Mometasone furoate; Nasal bioavailability

Indexed keywords

FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; DRUG URINE LEVEL; FEMALE; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; LIQUID; MALE; MEASUREMENT; NORMAL HUMAN; NOSE; NOSE CARTILAGE; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TIME;

EID: 3142722670     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0763-y     Document Type: Article

References (20)

1. Dolovich J, O'Connor M, Stepner N, Smith A, Sharma RK (1994) Double-blind comparison of intranasal fluticasone propionate, 200 micrograms, once daily with 200 micrograms twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed. Ann Allergy 72:435-440
2. Pedersen B, Dahl R, Richards DH (1995) Once daily fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Allergy 50:794-799
3. Hebert JR, Nolop K, Lutsky BN (1996) Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 51:569-576
4. Drouin M, Yang WH, Bertrand B (1996) Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 77:153-160
5. Daley-Yates PT, Baker R (2001) Systemic bioavailability of fluticasone propionate administered as nasal drops and the aqueous nasal spray formulations. Br J Clin Pharmacol 51:103-105
6. McDowell JE, Mackie AE, Ventresca GP, Bye A (1997) Pharmacokinetics and bioavailability of intranasal fluticasone in humans. Clin Drug Invest 1:44-52
7. Schering-Plough Research Institute (1998) SCH 32088: single dose absolute bioavailability study of mometasone nasal spray in volunteers with evidence of allergic rhinitis. Study No. C93-196 (data on file)
8. Callejas S, Biddlecombe R, Jones A, Joyce K, Pereira A, Pleasance S (1998) Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr 718:243-250
9. FDA Summary Basis of Approval (2000) NDA 20762, Nasonex Nasal Spray Medical Officer Review
10. Price AC, Daley-Yates PT, Wright AM, Callejas S (2000) Negligible absolute bioavailability and no HPA-axis effects after multiple 200 μg daily doses of Fluticasone propionate (FP) administered from the aqueous nasal spray (FPANS). Eur Resp J 16:279s
11. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N (2001) Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51:400-409
12. Jeal W, Faulds D (1997) Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 53:257-280
13. Thorsson L, Borga O, Edsbaker S (1999) Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray and powder. Br J Clin Pharmacol 47:619-624
14. Argenti D, Colligon I, Heald D (1994) Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide. J Clin Pharmacol 34:854-858
15. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM (1998) Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hyppthalamic-pituitary-adrenal axis. J Allergy Clin Immunol 102:191-197
16. Van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C (1991) Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 67:156-162
17. Brannan MD, Seiberling M, Cutler DL (1996) Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol 97:198
18. Brannan MD, Herron JM, Reidenberg P (1996) Lack of HPA axis suppression following 36 days of intranasal mometasone furoate. Ann Allergy Asthma Immunol 78:154
19. Crim C, Pierre LN, Daley-Yates PT (2001) A review of the pharmacology and pharmacokinetics of fluticasone propionate and mometosone furoate. Clin Therapeut 23:1339-1354
20. Daley-Yates PT, Richards DH (2001) Pharmacokinetic and pharmacodynamic relationships for intranasal corticosteroids (INCS). J Allergy Clin Immunol 107:8313